Association between Hb and IL-6 or hepcidin in patients with placebo and canakinumab treatment
| . | Association between hemoglobin and IL-6 . | Association between hemoglobin and hepcidin . | ||
|---|---|---|---|---|
| Hemoglobin increased and IL-6 decreased . | Hemoglobin decreased and IL-6 increased . | Hemoglobin increased and hepcidin decreased . | Hemoglobin decreased and hepcidin increased . | |
| Canakinumab | 1465 (51.5%) | 1380 (48.5%) | 1041 (38.2%) | 1684 (61.8%) |
| Placebo | 330 (23.5%) | 1075 (76.5%) | 338 (24.8%) | 1026 (75.2%) |
| OR (95% CI), P value | 3.46 (3.00-4.00), P < .001 | 1.88 (1.62-2.17), P < .001 | ||
| . | Association between hemoglobin and IL-6 . | Association between hemoglobin and hepcidin . | ||
|---|---|---|---|---|
| Hemoglobin increased and IL-6 decreased . | Hemoglobin decreased and IL-6 increased . | Hemoglobin increased and hepcidin decreased . | Hemoglobin decreased and hepcidin increased . | |
| Canakinumab | 1465 (51.5%) | 1380 (48.5%) | 1041 (38.2%) | 1684 (61.8%) |
| Placebo | 330 (23.5%) | 1075 (76.5%) | 338 (24.8%) | 1026 (75.2%) |
| OR (95% CI), P value | 3.46 (3.00-4.00), P < .001 | 1.88 (1.62-2.17), P < .001 | ||